# OnCo record act-iv (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/act-iv/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "act-iv", "NCT01480479" ;
  schema:name "ACT IV"@en ;
  schema:description "ACT IV was a double-blind phase 3 test of rindopepimut, a vaccine against the EGFRvIII mutant protein, in 745 patients with newly diagnosed glioblastoma. It showed no benefit over a control vaccine, and because both arms beat historical expectations it taught the field how misleading historical-control comparisons can be."@en ;
  schema:url <https://onco.cc/trials/act-iv/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01480479> ;
  onco:status "negative" ;
  onco:phase "3" ;
  schema:startDate "2011-11" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:technologies <https://onco.cc/technologies/shared-antigen-vaccine/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/rindopepimut/> ;
  onco:companies <https://onco.cc/companies/celldex/> ;
  onco:terms <https://onco.cc/terms/egfrviii/> .